Table 2:
Janus kinase inhibitor use in JDM
| Ruxolitinib (n) | Tofacitinib (n) | Baricitinib (n) | Reference |
|---|---|---|---|
| 1 | Aeshlimann et al. [59] | ||
| 1 | Papadopoulou et al. [58] | ||
| 2 | Sabbagh et al. [57] | ||
| 2 | Sozeri et al. [62] | ||
| 4 | Kim et al. [55] | ||
| 18 | 7 | Ding et al. [56] | |
| 3 | Yu et al. [61] | ||
| 7 | 3 | Voyer et al. [60] | |
| 1 | Heinen et al. [63] |
Reports of use of off-label Janus kinase (JAK) inhibitors in JDM are listed above chronologically with the number of patients on a given JAK inhibitor. Ruxolitinib and bariciitnib block JAK1 and JAK2. Tofacitinib blocks JAK1, JAK2, and JAK3.